This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription Service and Professional Service segments deliver an impressive performance in Q3.
Patterson Companies (PDCO) Q2 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2021 results benefit from strong segmental performance.
AMN Healthcare (AMN) Boosts Service Portfolio With New Offering
by Zacks Equity Research
AMN Healthcare's (AMN) new pledge to provide support minority-owned businesses, thereby helping them to thrive.
Align Technology (ALGN) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Align Technology (ALGN) is optimistic about maintaining a robust product portfolio along with strength in its international business.
Haemonetics (HAE) New Products Aid, Plasma Sales Remain Tepid
by Zacks Equity Research
Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.
NuVasive (NUVA) Launches C360 Portfolio for Cervical Spine
by Zacks Equity Research
The ACP system within NuVasive's (NUVA) C360 portfolio is targeted to reduce common postoperative complications.
Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus
by Zacks Equity Research
Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic
Why You Should Add Merit Medical (MMSI) to Your Portfolio
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, courtesy of its solid prospects.
Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis
by Zacks Equity Research
Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
by Zacks Equity Research
LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
by Zacks Equity Research
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
Hologic (HOLX) Gets Additional FDA Nod, to Aid HIV Testing
by Zacks Equity Research
Additional FDA approval for Hologic's (HOLX) molecular diagnostic test is expected to aid in the diagnosis of HIV infection.
CAH vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts
by Zacks Equity Research
Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
by Zacks Equity Research
Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.
Medtronic's (MDT) Q2 Earnings Beat Estimates, Margins Fall
by Urmimala Biswas
Deferred procedures due to the pandemic impact Medtronic's (MDT) Q2 performance.
Stock Market News for Nov 24, 2020
by Zacks Equity Research
Benchmarks closed higher on Monday after AstraZeneca and The University of Oxford said its coronavirus vaccine was up to 90% effective in trail.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.